| Literature DB >> 34416707 |
Frank Balis1, Daniel M Green2, Clarke Anderson3, Shelly Cook4, Jasreman Dhillon5, Kenneth Gow6, Susan Hiniker7, Rama Jasty-Rao8, Chi Lin9, Harold Lovvorn10, Iain MacEwan11, Julian Martinez-Agosto12, Elizabeth Mullen13, Erin S Murphy14, Mark Ranalli15, Daniel Rhee16, Denise Rokitka17, Elisabeth Lisa Tracy18, Tamara Vern-Gross19, Michael F Walsh20, Amy Walz21, Jonathan Wickiser22, Matthew Zapala23, Ryan A Berardi24, Miranda Hughes24.
Abstract
The NCCN Guidelines for Wilms Tumor focus on the screening, diagnosis, staging, treatment, and management of Wilms tumor (WT, also known as nephroblastoma). WT is the most common primary renal tumor in children. Five-year survival is more than 90% for children with all stages of favorable histology WT who receive appropriate treatment. All patients with WT should be managed by a multidisciplinary team with experience in managing renal tumors; consulting a pediatric oncologist is strongly encouraged. Treatment of WT includes surgery, neoadjuvant or adjuvant chemotherapy, and radiation therapy (RT) if needed. Careful use of available therapies is necessary to maximize cure and minimize long-term toxicities. This article discusses the NCCN Guidelines recommendations for favorable histology WT.Entities:
Mesh:
Year: 2021 PMID: 34416707 DOI: 10.6004/jnccn.2021.0037
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN: 1540-1405 Impact factor: 11.908